Melanoma brain metastases and vemurafenib: Need for further investigation

Mayo Clinic Proceedings

Volumn 87, Issue 10, 2012, Pages 976-981

  Rochet, Nicole M ^a   Dronca, Roxana S ^a   Kottschade, Lisa A ^a   Chavan, Rahul N ^a   Gorman, Brian ^a   Gilbertson, Julie R ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CORTICOSTEROID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PACLITAXEL; TEMOZOLOMIDE; VEMURAFENIB; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ADVANCED CANCER; ALTERNATIVE MEDICINE; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BRAF V600E GENE; BRAIN METASTASIS; BRAIN RADIATION; BRAIN REGION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARCINOMATOUS MENINGITIS; CASE REPORT; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOEMBOLIZATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CUTANEOUS MELANOMA; DIARRHEA; DROWSINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOOD AND DRUG ADMINISTRATION; GALLSTONE; GAMMA KNIFE RADIOSURGERY; GENE MUTATION; HEADACHE; HUMAN; LUNG NODULE; LYMPH NODE; MACULOPAPULAR RASH; MALE; MELANOMA; MEMORY DISORDER; METASTASIS POTENTIAL; MORBIDITY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PAPULAR RASH; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; SIDE EFFECT; STEROID THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; BRAIN TUMOR; DISEASE COURSE; DRUG ANTAGONISM; FATALITY; GENETICS; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; SKIN TUMOR;

ADULT; BRAIN NEOPLASMS; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84871900504     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.07.006     Document Type: Article

References (19)

1. Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am. 1996;7(3):337-344.
2. Davies MA, Liu P, McIntyre S, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687-1696.
3. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998; 88(1):11-20.
4. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22(7):1293-1300.
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
6. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239-1246.
7. Spittle C, Ward MR, Nathanson KL, et al. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn. 2007; 9(4):464-471.
8. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
9. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012; 123(2):223-233.
10. Colombino M, Capone M, Maio M, et al Italian Melanoma Intergroup (IMI). Mutation frequency in BRAF and NRAS genes among primary tumors and different types of metastasis from melanoma patients [abstract 8574]. J Clin Oncol (Meeting Abstracts). 2011;29(15, suppl):8574.
11. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N Engl J Med. 2011; 365(25):2439-2441.
12. Dummer R, Rinderknecht J, Goldinguer SM, et al. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases [abstract 8548]. J Clin Oncol (Meeting Abstracts). 2011;29(15, suppl):8548.
13. Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther. 2012;342(1):33-40.
14. Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 2001;24(12):719-725.
15. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract 8503]. J Clin Oncol (Meeting Abstracts). 2010; 28(15, suppl):8503.
16. Hauschild A, Grob JJ, Demidov LV, et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma [abstract LBA8500]. J Clin Oncol. 2012;30(15, suppl):LBA8500.
17. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012; 379(9829):1893-1901.
18. Kirkwood JM, Long GV, Trefzer U, et al. BREAK-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets). J Clin Oncol. 2012;30(15, suppl):8501.
19. Harding JJ, Pulitzer M, Chapman PB. Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med. 2012;366(9):866-868.